How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Burmese pythons are an invasive nightmare in Florida. Anyone can view a sampling of recent comments, but you must be a Times ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Attila covers software, apps and services, with a focus on virtual private networks. He's an advocate for digital privacy and has been quoted in online publications like Computer Weekly, The Guardian, ...

Joel O’Leary is a full-time Personal Finance Writer at Motley Fool Money, covering credit cards, bank accounts, investing, mortgages, and other personal finance topics. Joel has been writing about ...

Artificial intelligence is rewriting the world, and simultaneously inventing a whole new language to describe how it’s doing it. Sit in on any product meeting, pitch, or panel these days, and you’ll ...